Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Insider Sell: Regeneron Pharmaceuticals

08/09/2022 | 09:13am EDT


© MT Newswires 2022
All news about REGENERON PHARMACEUTICALS, INC.
09/20Decibel Therapeutics Files Investigational New Drug Application With US FDA for Product..
MT
09/16Regeneron pharmaceuticals, inc. - positive dupixent phase 3 data in children aged 6 mon..
AQ
09/16Regeneron - POSITIVE DUPIXENT (DUPILUMAB) PHASE 3 DATA IN CHILDREN AGED 6 MONTHS TO 5 Y..
AQ
09/16Intellia Therapeutics, Regeneron Say Genome Editing Therapy Reduced Protein Concentrati..
MT
09/16SECTOR UPDATE : Health Care Stocks Mixed Premarket Friday
MT
09/16Intellia Therapeutics, Regeneron Therapeutics Deliver Positive Early-Stage Data on ATTR..
MT
09/16Canaccord Genuity Adjusts Price Target on Regeneron Pharmaceuticals to $750 From $700, ..
MT
09/16Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Pha..
AQ
09/16Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Pha..
CI
09/16Regeneron Pharmaceuticals, Sanofi Say Atopic Dermatitis Drug Improved Skin Clearance in..
MT
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 834 M - -
Net income 2022 3 874 M - -
Net cash 2022 5 449 M - -
P/E ratio 2022 20,0x
Yield 2022 -
Capitalization 74 550 M 74 550 M -
EV / Sales 2022 5,84x
EV / Sales 2023 5,13x
Nbr of Employees 10 715
Free-Float 80,6%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 697,33 $
Average target price 747,86 $
Spread / Average Target 7,25%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.10.42%74 550
GILEAD SCIENCES, INC.-13.43%78 787
VERTEX PHARMACEUTICALS29.08%72 693
BIONTECH SE-50.21%31 192
WUXI APPTEC CO., LTD.-41.46%28 154
GENMAB A/S-7.22%20 810